Fosun and ElpasBio come together to promote AlloJoin® Stem Cell Therapy

Introduction

ElpasBio Holdings, a well-known, clinically promising biotechnology company, concentrates on regenerative medicine. This China-based company received its first recognition for its first stem cell drug, and the stamp of the FDA’s approval was a memorable milestone for the company. This approval helped the company to prove its potential in the Phase 3 clinical trial for knee osteoarthritis treatment.

Fosun Kairos is the China-based innovator making a name in the cell therapy sector and is also said to be the first ever industry to marketise CAR-T therapies in China. Fosun is determined to bring development and innovation to the various, unique product pipeline regardless of any application/areas.

Announcement

Fosun Kairos and ElpasBio Holdings entered a commercial deal for the investigational fundamental allogeneic human adipose-derived mesenchymal stem cell (haMPC) therapy, lotazadromcel. This therapy will be commercialised in Mainland China, Macau SAR and Hong Kong SAR for knee osteoarthritis (KOA).

AlloJoin® Stem Cell Therapy

ElpasBio’s AlloJoin® is the best-in-class, investigational stem cell product, produced totally internally with the company’s exclusive haMPC technology platform and is officially secured by genuine property rights that make this product safe and trustworthy. This therapy was discovered and considered for its skilled capabilities to offer timely and safe solutions for KOA patients to avoid inflammation.

The therapy is actively fixing the damaged cartilage and living up to the goal to achieve the position as the ‘first ever approved regenerative medicine product’. Recently, AlloJoin® has been under study in a Phase 3 pivotal clinical trial in KOA at China’s R&D lab, following the completion of Phase 1 and 2 clinical studies, which showed commendable results of improvement in KOA patients and addressed knee joint pain as well.

Complementing this brilliant study, Fosun’s marketing expertise and knowledge of market insights in the cell therapy market are a boon to this commercialisation deal. ElpasBio gave commercialisation authority to Fosun for its AlloJoin® in Macau SAR, Hong Kong SAR and Mainland China.

Chairman of ElpasBio, Tony (Bizuo) Liu, said, “Fosun have extensive track record in marketing cell therapies in China. This experience is a strong base for our comprehensive joint partnership. This collaborative agreement will elevate the marketing volume of AlloJoin® in China and get us closer to identifying the unmet medical needs of a degenerative disease (KOA).” Chairman of Fosun Kairos, Wenjie Zhang, also expressed its excitement for this partnership.